Cardiovascular Response To Early Sepsis

Sepsis, defined by consensus briefing as "the systemic inflammatory response syndrome (SIRS) that occurs during infection,"^one is generally viewed as a disease aggravated by the inappropriate immune response encountered in the affected individual (for review, encounter Hotchkiss and Karl² and Riedemann et al,ⁱⁱⁱ). The Table gives the electric current criteria for the establishment of the diagnosis of systemic inflammatory response syndrome, sepsis, and septic shock.^1,4 Morbidity and mortality are high, resulting in sepsis and septic daze existence the 10th most mutual crusade of decease in the Usa.⁵ The incidence of sepsis and sepsis-related deaths appears to be increasing past 1.5% per year.⁶ In a recent study,^six the total national hospital cost invoked past astringent sepsis in the United States was estimated at approximately $16.7 billion on the basis of an estimated severe sepsis rate of 751 000 cases per year with 215 000 associated deaths annually. A contempo study from U.k. documented a 46% in-hospital mortality rate for patients presenting with severe sepsis on access to the intensive care unit.⁷

**Electric current Criteria for Establishment of the Diagnosis of SIRS, Sepsis, and Septic Daze** ^1,4
SIRS indicates systemic inflammatory response syndrome.
SIRS	Two or more of the following:
	Trunk temperature >38.5°C or <35.0°C
	Centre rate >90 bpm
	Respiratory rate >20 breaths per minute or arterial CO₂ tension <32 mm Hg or need for mechanical ventilation
	White blood prison cell count >12 000/mm³ or <4000/mm^three or immature forms >10%
Sepsis	SIRS and documented infection (culture or Gram stain of blood, sputum, urine, or normally sterile trunk fluid positive for pathogenic microorganism; or focus of infection identified by visual inspection, eg, ruptured bowel with free air or bowel contents institute in belly at surgery, wound with purulent discharge)
Severe sepsis	Sepsis and at to the lowest degree ane sign of organ hypoperfusion or organ dysfunction:
	Areas of mottled skin
	Capillary refilling fourth dimension ≥iii s
	Urinary output <0·5 mL/kg for at least i h or renal replacement therapy
	Lactates >two mmol/L
	Abrupt change in mental status or aberrant electroencephalogram
	Platelet counts <100 000/mL or disseminated intravascular coagulation
	Astute lung injury—astute respiratory distress syndrome
	Cardiac dysfunction (echocardiography)
Septic stupor	Severe sepsis and ane of the following:
	Systemic mean blood pressure level <60 mm Hg (<80 mm Hg if previous hypertension) afterward 20–xxx mL/kg starch or xl–sixty mL/kg serum saline, or pulmonary capillary wedge pressure between 12 and xx mm Hg
	Need for dopamine >5 μg · kg⁻¹ · min⁻¹ or norepinephrine or epinephrine <0.25 μg · kg^−ane · min^−ane to maintain hateful blood pressure above 60 mm Hg (80 mm Hg if previous hypertension)
Refractory septic shock	Need for dopamine >15 μg · kg⁻¹ · min⁻¹ or norepinephrine or epinephrine >0.25 μg · kg⁻¹ · min^−one to maintain mean claret pressure level above 60 mm Hg (fourscore mm Hg if previous hypertension)

As an of import organ system frequently affected by sepsis and always afflicted by septic shock, the cardiovascular system and its dysfunction during sepsis accept been studied in clinical and basic research for more than than v decades. In 1951, Waisbren was the get-go to describe cardiovascular dysfunction due to sepsis.⁸ He recognized a hyperdynamic state with full bounding pulses, flushing, fever, oliguria, and hypotension. In addition, he described a second, smaller patient group who presented clammy, pale, and hypotensive with depression book pulses and who appeared more severely ill. With retrospect, the latter group might well take been book underresuscitated, and indeed, timely and adequate book therapy has been demonstrated to be one of the most effective supportive measures in sepsis therapy.^nine

Under weather condition of acceptable book resuscitation, the profoundly reduced systemic vascular resistance typically encountered in sepsis^x leads to a concomitant elevation in cardiac index that obscures the myocardial dysfunction that also occurs. Nonetheless, as early as the mid-1980s, pregnant reductions in both stroke volume and ejection fraction in septic patients were observed despite normal total cardiac output.¹¹ Importantly, the presence of cardiovascular dysfunction in sepsis is associated with a significantly increased bloodshed rate of 70% to xc% compared with 20% in septic patients without cardiovascular harm.¹² Thus, myocardial dysfunction in sepsis has been the focus of intense enquiry activity. Although a number of mediators and pathways have been shown to exist associated with myocardial depression in sepsis, the precise cause remains unclear.

The purpose of the present review is to delineate some characteristics of septic myocardial dysfunction, to assess the most commonly cited and reported underlying mechanisms of cardiac dysfunction in sepsis, and to briefly outline current therapeutic strategies and possible future approaches. This review is not intended to be all inclusive.

Characteristics of Myocardial Dysfunction in Sepsis

Using portable radionuclide cineangiography, Calvin et al^thirteen were the first to demonstrate myocardial dysfunction in adequately volume-resuscitated septic patients with decreased ejection fraction and increased end-diastolic volume index. Adding pulmonary artery catheters to series radionuclide cineangiography, Parker and colleagues¹¹ extended these observations with the 2 major findings that (one) survivors of septic shock were characterized by increased end-diastolic volume index and decreased ejection fraction, whereas nonsurvivors typically maintained normal cardiac volumes, and (2) these acute changes in stop-diastolic book index and ejection fraction, although sustained for several days, were reversible. More recently, echocardiographic studies have demonstrated impaired left ventricular systolic and diastolic part in septic patients.^14–16 These human studies, in conjunction with experimental studies ranging from the cellular level¹⁷ to isolated middle studies^eighteen,19 and to in vivo animate being models,^twenty–22 accept clearly established decreased contractility and dumb myocardial compliance equally major factors that cause myocardial dysfunction in sepsis.

All the same the functional and structural differences between the left and right ventricle, similar functional alterations, as discussed above, take been observed for the right ventricle, which suggests that correct ventricular dysfunction in sepsis closely parallels left ventricular dysfunction.^23–26 Nevertheless, the relative contribution of the right ventricle to septic cardiomyopathy remains unknown.

Myocardial dysfunction in sepsis has also been analyzed with respect to its prognostic value. Parker et al,²⁷ reviewing septic patients on initial presentation and at 24 hours to determine prognostic indicators, found a eye charge per unit of <106 bpm to exist the only cardiac parameter on presentation that predicted a favorable outcome. At 24 hours later presentation, a systemic vascular resistance alphabetize >1529 dyne · s^−one · cm^−v · one thousand⁻², a centre charge per unit <95 bpm or a reduction in eye rate >xviii bpm, and a cardiac index >0.five L · min⁻¹ · thousand⁻² suggested survival.²⁷ In a prospective study, Rhodes et al²⁸ demonstrated the feasibility of a dobutamine stress examination for outcome stratification, with nonsurvivors being characterized by an attenuated inotropic response. The well-established biomarkers in myocardial ischemia and heart failure, cardiac troponin I and T, as well as B-blazon natriuretic peptide, have also been evaluated with regard to sepsis-associated myocardial dysfunction. Although B-type natriuretic peptide studies have delivered conflicting results in septic patients (for review, come across Maeder et al²⁹), several small studies have reported a relationship between elevated cardiac troponin T and I and left ventricular dysfunction in sepsis, as assessed by echocardiographic ejection fraction^30–33 or pulmonary artery catheter–derived left ventricular stroke piece of work index.³⁴ Cardiac troponin levels also correlated with the elapsing of hypotension³⁵ and the intensity of vasopressor therapy.³⁴ In addition, increased sepsis severity, measured by global scores such as the Simplified Acute Physiology Score II (SAPS II) or the Acute Physiology And Chronic Wellness Evaluation Ii score (APACHE 2), was associated with increased cardiac troponin levels,^31,33 as was poor curt-term prognosis.^32,33,35,36 Despite the heterogeneity of study populations and type of troponin studied, the mentioned studies were univocal in concluding that elevated troponin levels in septic patients reflect higher disease severity, myocardial dysfunction, and worse prognosis. In a recent meta-assay of 23 observational studies, Lim et al³⁷ found cardiac troponin levels to be increased in a large percentage of critically ill patients. Furthermore, in a subset of studies that permitted adjusted analysis and comprised 1706 patients, this troponin pinnacle was associated with an increased hazard of death (odds ratio, two.five; 95% CI, i.nine to 3.4, P<0.001)³⁷; however, the underlying mechanisms clearly require further research.

Thus, it appears reasonable to recommend inclusion of cardiac troponins in the monitoring of patients with severe sepsis and septic shock to facilitate prognostic stratification and to increase alertness to the presence of cardiac dysfunction in individual patients. However, it remains to be shown whether risk stratification based on cardiac troponins can identify patients in whom aggressive therapeutic regimens might reap the greatest benefit and so translate into a survival do good.

Mechanisms Underlying Myocardial Dysfunction in Sepsis

Cardiac low during sepsis is probably multifactorial (Figure). Nevertheless, it is important to identify individual contributing factors and mechanisms to generate worthwhile therapeutic targets. As a consequence, a vast assortment of mechanisms, pathways, and disruptions in cellular homeostasis have been examined in septic myocardium.

Synopsis of potential underlying mechanisms in septic myocardial dysfunction. MDS indicates myocardial depressant substance.

Global Ischemia

An early theory of myocardial low in sepsis was based on the hypothesis of global myocardial ischemia; however, septic patients take been shown to have high coronary claret flow and diminished coronary avenue–coronary sinus oxygen difference.³⁸ As in the peripheral circulation, these alterations can be attributed to disturbed menstruum autoregulation or disturbed oxygen utilization.^39,xl Coronary sinus blood studies in patients with septic shock have also demonstrated complex metabolic alterations in septic myocardium, including increased lactate extraction, decreased free fat acid extraction, and decreased glucose uptake.⁴¹ Furthermore, several magnetic resonance studies in animal models of sepsis have demonstrated the presence of normal high-free energy phosphate levels in the myocardium.^42,43 It has likewise been proposed that myocardial dysfunction in sepsis may reflect hibernating myocardium.⁴⁴ To achieve this conclusion, Levy et al⁴⁴ studied a murine cecal ligation and double-puncture model and observed diminished cardiac functioning, increased myocardial glucose uptake, and deposits of glycogen in a setting of preserved arterial oxygen tension and myocardial perfusion. Although all of the above-mentioned findings reflect important alterations in coronary flow and myocardial metabolism, mirroring effects observed in peripheral circulation during sepsis, at that place is no evidence supporting global ischemia as an underlying crusade of myocardial dysfunction in sepsis. Yet, in septic patients with coexistent and maybe undiagnosed coronary artery disease (CAD), regional myocardial ischemia or infarction secondary to CAD may certainly occur. The manifestation of myocardial ischemia due to CAD might even be facilitated past the volatile hemodynamics in sepsis, also as by the generalized microvascular dysfunction so oftentimes observed in sepsis.⁴⁵ Additional CAD-aggravating factors encountered in sepsis embrace generalized inflammation and the activated coagulatory system. Furthermore, the endothelium plays a prominent role in sepsis (see below), merely little is known of the impact of preexisting, CAD-associated endothelial dysfunction in this context. In a postmortem study of 21 fatal cases of septic shock, previously undiagnosed myocardial ischemia at least contributed to death in 7 of the 21 cases (all 21 patients were males, with a hateful historic period of lx.4 years).⁴⁶ Information technology certainly appears prudent to remain wary of CAD complications while treating sepsis, especially in patients with identifiable risk factors and in view of the ever-increasing hateful historic period of intensive care unit patients and including septic patients.

Myocardial Depressant Substance

A circulating myocardial depressant cistron in septic shock was offset proposed more than than 50 years ago.⁴⁷ Parrillo et al⁴⁸ quantitatively linked the clinical degree of septic myocardial dysfunction with the effect the serum, taken from respective patients, had on rat cardiac myocytes, with clinical severity correlating well with the decrease in extent and velocity of myocyte shortening. These effects were not seen when serum from ambulatory patients whose cardiac function had returned to normal was practical or when serum was obtained from other critically ill, nonseptic patients.⁴⁸ In extension of these findings, ultrafiltrates from patients with astringent sepsis and simultaneously reduced left ventricular stroke piece of work index (<30 g · chiliad⁻¹ · thou⁻²) displayed cardiotoxic effects and contained significantly increased concentrations of interleukin (IL)-ane, IL-eight, and C3a.⁴⁹ Recently, Mink et al⁵⁰ demonstrated that lysozyme c, a bacteriolytic agent believed to originate mainly from disintegrating neutrophilic granulocytes and monocytes, mediates cardiodepressive furnishings during Escherichia coli sepsis and, importantly, that competitive inhibition of lysozyme c can forbid myocardial low in the respective experimental sepsis model. Additional potential candidates for myocardial depressant substance include other cytokines, prostanoids, and nitric oxide (NO). Some of these will be discussed beneath.

Cytokines

Infusion of lipopolysaccharide (LPS, an obligatory component of Gram-negative bacterial cell walls) into both animals and humans⁵¹ partially mimics the hemodynamic effects of septic shock.^51,52 However, simply a minority of patients with septic shock have detectable LPS levels, and the prolonged time course of septic myocardial dysfunction and the chemic characteristics of LPS are non consistent with LPS representing the sole myocardial depressant substance.^48,53 Tumor necrosis factor-α (TNF-α) is an of import early mediator of endotoxin-induced daze.⁵⁴ TNF-α is derived from activated macrophages, but contempo studies have shown that TNF-α is as well secreted by cardiac myocytes in response to sepsis.⁵⁵ Although awarding of anti-TNF-α antibodies improved left ventricular function in patients with septic shock,⁵⁶ subsequent studies using monoclonal antibodies directed against TNF-α or soluble TNF-α receptors failed to improve survival in septic patients.^57–59 IL-ane is synthesized past monocytes, macrophages, and neutrophils in response to TNF-α and plays a crucial role in the systemic allowed response. IL-1 depresses cardiac contractility by stimulating NO synthase (NOS).⁶⁰ Transcription of IL-1 is followed past delayed transcription of IL-one receptor antagonist (IL-one-ra), which functions as an endogenous inhibitor of IL-one. Recombinant IL-ane-ra was evaluated in phase III clinical trials, which showed a tendency toward improved survival⁶¹ and increased survival time in a retrospective analysis of the patient subgroup with the most severe sepsis⁶²; however, to date, this initially promising therapy has failed to deliver a statistically pregnant survival benefit. IL-six, another proinflammatory cytokine, has as well been implicated in the pathogenesis of sepsis and is considered a more than consistent predictor of sepsis than TNF-α because of its prolonged elevation in the circulation.⁶³ Although cytokines may very well play a key function in the early on decrease in contractility, they cannot explicate the prolonged elapsing of myocardial dysfunction in sepsis, unless they upshot in the induction or release of additional factors that in turn alter myocardial function, such as prostanoids or NO.^64,65

Prostanoids

Prostanoids are produced by the cyclooxygenase enzyme from arachidonic acid. The expression of cyclooxygenase enzyme-2 is induced, amidst other stimuli, by LPS and cytokines (cyclooxygenase enzyme-1 is expressed constitutively).⁶⁶ Elevated levels of prostanoids such equally thromboxane and prostacyclin, which have the potential to change coronary autoregulation, coronary endothelial function, and intracoronary leukocyte activation, accept been demonstrated in septic patients.⁶⁷ Early animal studies with cyclooxygenase inhibitors such as indomethacin yielded very promising results.^68,69 Along with other positive results, these led to an important clinical study involving 455 septic patients who were randomized to receive intravenous ibuprofen or placebo.⁷⁰ Unfortunately, that study did non demonstrate improved survival for the treatment arm. Similarly, a more recent, smaller written report on the furnishings of lornoxicam failed to provide evidence for a survival benefit through cyclooxygenase inhibition in sepsis.⁷¹ Animal studies aimed at elucidating possible benefits of isotype-selective cyclooxygenase inhibition have and then far produced conflicting results.^72,73

Endothelin-i

Endothelin-ane (ET-1; for an in-depth review of endothelin in sepsis, see Gupta et al⁷⁴) upregulation has been demonstrated within vi hours of LPS-induced septic shock.⁷⁵ Cardiac overexpression of ET-1 triggers an increase in inflammatory cytokines (among others, TNF-α, IL-1, and IL-6), interstitial inflammatory infiltration, and an inflammatory cardiomyopathy that results in heart failure and death.⁷⁶ The interest of ET-1 in septic myocardial dysfunction is supported by the observation that tezosentan, a dual endothelin-A and endothelin-B receptor antagonist, improved cardiac index, stroke volume index, and left ventricular stroke work index in endotoxemic shock.⁷⁷ However, higher doses of tezosentan exhibited cardiotoxic effects and led to increased bloodshed.⁷⁷ Although ET-ane has been demonstrated to exist of pathophysiological importance in a broad array of cardiac diseases through autocrine, endocrine, or paracrine effects, its biosynthesis, receptor-mediated signaling, and functional consequences in septic myocardial dysfunction warrant further investigation to assess the therapeutic potential of ET-1 receptor antagonists.

Nitric Oxide

NO exerts a plethora of biological effects in the cardiovascular system.⁷⁸ It has been shown to attune cardiac function under physiological and a multitude of pathophysiological weather condition. In healthy volunteers, low-dose NO increases LV function, whereas inhibition of endogenous NO release past intravenous infusion of the NO synthase (NOS) inhibitor N ¹⁰⁰⁰-monomethyl-fifty-arginine reduced the stroke volume index.⁷⁹ College doses of NO have been shown to induce contractile dysfunction by depressing myocardial energy generation.⁸⁰ The absence of the of import NO scavenger myoglobin (Mb) in Mb knockout mice results in impaired cardiac part that is partially reversible by NOS inhibition.⁸¹ Endogenous NO contributes to hibernation in response to myocardial ischemia by reducing oxygen consumption and preserving calcium sensitivity and contractile function.⁸² NO also represents a potent modulator of myocardial ischemia/reperfusion injury. Still, as in sepsis-related NO research, the reported furnishings of NO on ischemia/reperfusion injury are inconsistent owing to a multitude of misreckoning experimental factors.⁸³

Sepsis leads to the expression of inducible NOS (iNOS) in the myocardium,^84,85 followed past high-level NO production, which in turn chiefly contributes to myocardial dysfunction, in role through the generation of cytotoxic peroxynitrite, a product of NO and superoxide (for an excellent review, come across Pacher et al⁸⁶). In iNOS-scarce mice, cardiac function is preserved after endotoxin challenge.⁸⁷ Nonspecific NOS inhibition restores cardiac output and stroke volume later LPS injection.⁸⁸ Strikingly, in septic patients, infusion of methylene blue, a nonspecific NOS inhibitor, improves mean arterial pressure level, stroke volume, and left ventricular stroke work and decreases the requirement for inotropic support but, unfortunately, does not alter result.⁸⁹ An interesting report comparing the inhibition of NO superoxide and peroxynitrite in cytokine-induced myocardial contractile failure constitute peroxynitrite to indeed be the most promising therapeutic target.⁹⁰ It has too been proposed that the constitutively expressed mitochondrial isoform of NOS (mtNOS), the expression of which tin exist augmented by induction, controls rates of oxidative phosphorylation by inhibiting various steps of the respiratory chain.⁹¹ Although this hypothesis would provide a plausible explanation for the reduced coronary oxygen extraction observed during sepsis (see higher up), the effects of sepsis on expression of mtNOS and NO generation remain to be explored. Furthermore, the constitutively expressed endothelial NOS (eNOS), previously neglected in the context of sepsis, has been shown to exist an important regulator of iNOS expression, resulting in a more stable hemodynamic condition in eNOS-scarce mice after endotoxemia.⁹² Very recently, a functional NOS in red blood cells (rbcNOS) was identified that regulates deformability of erythrocyte membranes and inhibits activation of platelets.⁹³ With both outcome targets thus far demonstrated for rbcNOS lying at the core of microvascular dysfunction in sepsis, this discovery opens a whole new window to NO-related sepsis inquiry. Given the beingness of dissimilar NOS isoforms and their various modulating interactions, dose-dependent NO effects, and the precise residual of NO, superoxide, and thus peroxynitrite generated in subcellular compartments, further advances in our understanding of the complex NO biological science and its derived reactive nitrogen species concord the promise of revealing new, more specific and effective therapeutic targets.

Adhesion Molecules

Surface-expression upregulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 has been demonstrated in murine coronary endothelium and cardiomyocytes later on LPS and TNF-α stimulation.⁹⁴ Subsequently cecal ligation and double puncture, myocardial intercellular adhesion molecule-i expression increases in rats.⁹⁵ Vascular jail cell adhesion molecule-1 blockade with antibodies has been shown to prevent myocardial dysfunction and decrease myocardial neutrophil accumulation,^94,96 whereas both knockout and antibody blockade of intercellular adhesion molecule-ane ameliorate myocardial dysfunction in endotoxemia without affecting neutrophil aggregating.⁹⁴ In addition, neutrophil depletion does not protect against septic cardiomyopathy, which suggests that the cardiotoxic potential of neutrophils infiltrating the myocardium is of bottom importance in this context.⁹⁴ Other aspects of adhesion molecules are discussed in conjunction with possible statin furnishings below.

Therapeutic Approaches: The Present and the Future

A detailed discussion of therapeutic options in septic patients would conspicuously be beyond the scope of this review, and readers are kindly referred to the multiple excellent reviews published on the subject (eg, Hotchkiss and Karl,^two Annane et al,⁴ and Dellinger et al⁹⁷). Although a number of preventive measures, such equally prophylactic antibiotics, maintenance of normoglycemia, selective digestive tract decontamination, vaccines, and intravenous immunoglobulin, have shown benefit in distinct patient populations, preventive strategies with a broader aim remain elusive. One time sepsis is manifest (come across the Tabular array for criteria), prompt and acceptable antibiotic therapy accompanied by surgical removal of the infectious focus, if indicated and feasible, is the mainstay and too the but strictly causal line of therapy. In the presence of astringent sepsis and septic shock, supportive treatment in addition to causal therapy is mandatory. Supportive therapy encompasses early and goal-directed fluid resuscitation,⁹ vasopressor and inotropic therapy, red blood cell transfusion, mechanical ventilation, and renal back up when indicated. It is very likely benign to monitor cardiac performance in these patients. A wide array of techniques are available for this purpose, ranging from echocardiography to pulmonary catheters, thermodilution techniques, and pulse pressure analysis.⁹⁸ Because none of these techniques take demonstrated superiority, physicians should employ the method with which they are most familiar. Whichever method is called, it should be applied frequently to tailor supportive therapy to the individual patient and to achieve the "gilt standard" of early goal-directed therapy. In contempo years, several attempts take been made to therapeutically address myocardial dysfunction in sepsis. Although the combination of norepinephrine as vasopressor and dobutamine equally inotropic agent is probably the nearly ofttimes applied in septic shock, at that place is currently no evidence to recommend one catecholamine over the other.⁹⁷ In homo endotoxemia, epinephrine has been demonstrated to inhibit proinflammatory pathways and coagulation activation, as well equally to augment antiinflammatory pathways,^99,100 whereas no immunomodulatory or coagulant effects could exist demonstrated for dobutamine in a similar setting.¹⁰¹ Isoproterenol has recently been applied successfully in a small group of patients with septic stupor, no known history of CAD, and inappropriate mixed venous oxygen concentration despite correction of hypoxemia and anemia.¹⁰² In a cecal ligation and double-puncture model of sepsis, the β-blocker esmolol given continuously later sepsis induction improved myocardial oxygen utilization and attenuated myocardial dysfunction,¹⁰³ which suggests that therapeutic strategies proven in ischemic heart failure might besides hold promise in septic cardiomyopathy. However, the optimal style of β-receptor stimulation (or indeed inhibition) to limit myocardial dysfunction remains a wide-open field for inspired investigation.

Given the generally accepted view of sepsis equally a disease largely propelled by an inappropriate immune response, numerous basic inquiry and clinical trials accept been undertaken to curb the lethal toll of sepsis through modulation of this uncontrolled immune response.^ii,3 To appointment, activated poly peptide C¹⁰⁴ and low-dose hydrocortisone¹⁰⁵ have emerged as the only inflammation-modulating substances that have been confirmed to be of benefit in patients with astringent sepsis and septic stupor. Over the by years, increasing evidence has accumulated that suggests that inhibitors of iii-hydroxy-3-methylglutaryl coenzyme A reductase, or statins, have therapeutic benefits independent of cholesterol lowering, termed "pleiotropic" effects. These accept added a wide telescopic of potential targets for statin therapy that range from decreasing renal part loss¹⁰⁶ and lowering bloodshed in patients with diastolic heart failure¹⁰⁷ to prevention and handling of stroke,¹⁰⁸ to name just a few. These pleiotropic effects include antiinflammatory and antioxidative properties, improvement of endothelial function, and increased NO bioavailability and thus might contribute to the benefit observed with statin therapy. Notably, these important immunomodulatory effects of statins have been demonstrated to be contained of lipid lowering¹⁰⁹ and appear to exist mediated via interference with the synthesis of mevalonate metabolites (nonsteroidal isoprenoid products). Blockade of the mevalonate pathway has been shown to suppress T-prison cell responses,¹¹⁰ reduce expression of class II major histocompatibility complexes on antigen presenting cells,¹⁰⁹ and inhibit chemokine synthesis in peripheral blood mononuclear cells.¹¹¹ Furthermore, CD11b integrin expression and CD11b-dependent adhesion of monocytes have been found to be adulterate by the initiation of statin treatment in hypercholesterolemic patients.¹¹² In this context, Yoshida et al¹¹³ take reported that statins reduce the expression of both monocytic and endothelial adhesion molecules, eg, the integrin leukocyte function-associated antigen-1 (LFA-one), via an inhibition of Rho GTPases, in particular their membrane anchoring by geranylation. In improver, mechanisms for antiinflammatory actions of statins have been revealed that are not related to the isoprenoid metabolism. For instance, Weitz-Schmidt et al¹¹⁴ take identified that some statins act as direct antagonists of LFA-1 attributable to their chapters to demark to the regulatory site in the LFA-ane i-domain. In addition to these multifaceted antiinflammatory effects, statins may interfere with activation of the coagulation cascade, as illustrated by the suppression of LPS-induced monocyte tissue cistron in vitro.¹¹⁵ Beyond their immunomodulatory functions, statins have been shown to exert direct antichlamydial effects during pulmonary infection with Chlamydia pneumoniae in mice,¹¹⁶ and a recent study suggests the benefit of statins may also extend to viral pathogens.¹¹⁷

Given the strong impact of statins on inflammation, statins might represent a welcome enforcement in the battle against severe infectious diseases such as sepsis. Consequently, several investigators have evaluated the role of statins in the prevention and treatment of sepsis. In a retrospective analysis, Liappis et al¹¹⁸ demonstrated a reduced overall and attributable mortality in patients with bacteremia who were treated concomitantly with statins. Pretreatment with simvastatin has been shown to profoundly better survival in a polymicrobial murine model of sepsis past preservation of cardiovascular function and inhibition of inflammatory alterations.^nineteen Encouraged past these findings, the same model was used to successfully treat sepsis in a clinically feasible mode, ie, handling was initiated several hours after the onset of sepsis. With dissimilar statins (atorvastatin, pravastatin, and simvastatin) existence effective, the therapeutic potential of statins in sepsis appears to exist a class result.²² Recently, Steiner et al¹¹⁹ observed that pretreatment with simvastatin can suppress the inflammatory response induced past LPS in healthy human volunteers. Furthermore, in a prospective observational cohort study in patients with astute bacterial infections performed by Almog et al,¹²⁰ previous treatment with statins was associated with a considerably reduced rate of severe sepsis and intensive care unit admissions. A total of 361 patients were enrolled in that study, and 82 of these patients had been treated with statins for at least 4 weeks earlier their access. Astringent sepsis developed in 19% of patients in the no-statin grouping compared with but 2.4% in patients who were taking statins. The intensive care unit admission rates were 12.2% for the no-statin group and 3.7% for the statin group. Because of the number of patients enrolled, the study was not powered to detect differences in mortality, although the large upshot on sepsis rate and intensive intendance unit admission were at least suggestive. Equally the most contempo development in this field, Hackam et al¹²¹ take produced an impressive observational study by initial evaluation of 141 487 cardiovascular patients, which resulted in a well-paired and homogenous report cohort of 69 168 patients afterward propensity-based matching. Drawing from this solid base, Hackam and coauthors were able to support the determination that statin therapy is associated with a considerably decreased rate of sepsis (hazard ratio, 0.81; 95% CI, 0.72 to 0.ninety), severe sepsis (risk ratio, 0.83; 95% CI, 0.seventy to 0.97), and fatal sepsis (risk ratio, 0.75; 95% CI, 0.61 to 0.93). This protective effect prevailed at both high and low statin doses and for several clinically important subpopulations, such equally diabetic and heart failure patients.

As has been suggested previously,¹²² statins might provide cumulative do good by reducing mortality from cardiovascular and infectious diseases such as sepsis. However, statins may have detrimental effects in distinct subsets of patients. Therefore, caution should prevail, and the use of statins in patients with sepsis must be accompanied by meticulous monitoring of unexpected side effects and well-designed randomized, controlled clinical trials.

Across an apparent rationale for randomized trials on statins in sepsis, information technology is notable that the results with other immunomodulatory approaches in sepsis have yielded rather limited success. For instance, utilise of the anti-TNF antibiotic F(ab′)two fragment afelimomab led to a significant simply rather modest reduction in risk of death and to improved organ-failure scores in patients with astringent sepsis and elevated IL-6 levels.¹²³ Moreover, a selective inhibitor of group IIA secretory phospholipase A2 failed to ameliorate clinical outcome for patients with severe sepsis, with a negative trend most pronounced among patients with cardiovascular failure.¹²⁴ Hence, considering none of the available strategies proven to be effective in sepsis are designed specifically to target myocardial dysfunction, one might conclude that strategies that preferentially accost cardiac morbidity in sepsis may be a promising surface area for investigation. For instance, lipoteichoic acid, a major virulence factor in Gram-positive sepsis, causes cardiac low past activating myocardial TNF-α synthesis via CD14 and induces coronary vascular disturbances by activating thromboxane ii synthesis. It thus contributes to cardiac depression and may therefore be a worthwhile and cardiac-specific target.¹²⁵ The implications of intensified efforts in the search for successful novel approaches to the treatment of myocardial dysfunction in sepsis may be considerable with regard to improved patient care that results in reduced bloodshed. This is of major significance in view of the substantial economic consequences of increasing sepsis morbidity in an aging population.

Sources of Funding

The present piece of work was supported by the Deutsche Forschungsgemeinschaft (Me1821/2, Me1821/3, and We1913/11) and the Interdisciplinary Center for Clinical Inquiry (IZKF Biomat).

Disclosures

None.

Footnotes

Correspondence to Marc W. Merx, Dr., Medizinische Klinik I, Universitätsklinikum der RWTH Aachen, Pauwelstraße 30, 52057 Aachen, Germany (electronic mail [email protected]), or Christian Weber, MD, Institut für Kardiovaskuläre Molekularbiologie, Universitätsklinikum der RWTH Aachen, Pauwelstraße xxx, 52057 Aachen, Germany (eastward-post [email protected]).

References

one Os RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the employ of innovative therapies in sepsis. Chest . 1992; 101: 1644–1655.CrossrefMedlineGoogle Scholar
two Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med . 2003; 348: 138–150.CrossrefMedlineGoogle Scholar
iii Riedemann NC, Guo R, Ward PA. Novel strategies for the treatment of sepsis. Nat Med . 2003; 9: 517–524.CrossrefMedlineGoogle Scholar
four Annane D, Bellissant E, Cavaillon JM. Septic stupor. Lancet . 2005; 365: 63–78.CrossrefMedlineGoogle Scholar
5 Martin GS, Mannino DM, Eaton S, Moss K. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med . 2003; 348: 1546–1554.CrossrefMedlineGoogle Scholar
6 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont K, Carcillo J, Pinsky MR. Epidemiology of astringent sepsis in the United States: analysis of incidence, outcome, and associated costs of intendance. Crit Care Med . 2001; 29: 1303–1310.CrossrefMedlineGoogle Scholar
seven Padkin A, Goldfrad C, Brady AR, Young D, Black North, Rowan G. Epidemiology of astringent sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med . 2003; 31: 2332–2338.CrossrefMedlineGoogle Scholar
viii Waisbren BA. Bacteremia due to gram-negative bacilli other than the Salmonella: a clinical and therapeutic report. AMA Arch Intern Med . 1951; 88: 467–488.CrossrefMedlineGoogle Scholar
nine Rivers East, Nguyen B, Havstad Due south, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich G; Early Goal-Directed Therapy Collaborative Group. Early on goal-directed therapy in the handling of severe sepsis and septic shock. Due north Engl J Med . 2001; 345: 1368–1377.CrossrefMedlineGoogle Scholar
10 Bone RC. Gram-negative sepsis: groundwork, clinical features, and intervention. Chest . 1991; 100: 802–808.CrossrefMedlineGoogle Scholar
xi Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound just reversible myocardial depression in patients with septic daze. Ann Intern Med . 1984; 100: 483–490.CrossrefMedlineGoogle Scholar
12 Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med . 1990; 113: 227–242.CrossrefMedlineGoogle Scholar
xiii Calvin JE, Driedger AA, Sibbald WJ. An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Breast . 1981; eighty: 579–586.CrossrefMedlineGoogle Scholar
14 Jafri SM, Lavine S, Field BE, Bahorozian MT, Carlson RW. Left ventricular diastolic function in sepsis. Crit Care Med . 1990; 18: 709–714.CrossrefMedlineGoogle Scholar
15 Munt B, Jue J, Gin Thou, Fenwick J, Tweeddale M. Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med . 1998; 26: 1829–1833.CrossrefMedlineGoogle Scholar
16 Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic role in septic shock. Intensive Care Med . 1997; 23: 553–560.CrossrefMedlineGoogle Scholar
17 Ren J, Ren BH, Sharma Air-conditioning. Sepsis-induced depressed contractile part of isolated ventricular myocytes is due to altered calcium transient properties. Shock . 2002; 18: 285–288.CrossrefMedlineGoogle Scholar
18 McDonough KH, Smith T, Patel K, Quinn Chiliad. Myocardial dysfunction in the septic rat middle: office of nitric oxide. Shock . 1998; x: 371–376.CrossrefMedlineGoogle Scholar
19 Merx MW, Liehn EA, Janssens U, Lütticken R, Schrader J, Hanrath P, Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation . 2004; 109: 2560–2565.LinkGoogle Scholar
20 Natanson C, Fink MP, Ballantyne HK, Mac Vittie TJ, Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates man septic shock. J Clin Invest . 1986; 78: 259–270.CrossrefMedlineGoogle Scholar
21 Stahl TJ, Alden PB, Ring WS, Madoff RC, Cerra FB. Sepsis-induced diastolic dysfunction in chronic canine peritonitis. Am J Physiol Heart Circ Physiol . 1990; 258: H625–H633.CrossrefGoogle Scholar
22 Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C. Statin handling afterwards onset of sepsis in a murine model improves survival. Circulation . 2005; 112: 117–124.LinkGoogle Scholar
23 Vincent JL, Thirion Yard, Brimioulle S, Lejeune P, Kahn RJ. Thermodilution measurement of right ventricular ejection fraction with a modified pulmonary avenue catheter. Intensive Care Med . 1986; 12: 33–38.CrossrefMedlineGoogle Scholar
24 Dhainaut JF, Brunet F, Monsaillier JF, Villemant D, Devaux JY, Konno M, De Gournay JM, Armaganidis A, Iotti Grand, Huyghebaert MF. Bedside evaluation of right ventricular performance using a rapid computerized thermodilution method. Crit Care Med . 1987; 15: 148–152.CrossrefMedlineGoogle Scholar
25 Dhainaut JF, Lanore JJ, de Gournay JM, Huyghebaert MF, Brunet F, Villemant D, Monsallier JF. Right ventricular dysfunction in patients with septic shock. Intensive Care Med . 1988; 14: 488–491.CrossrefMedlineGoogle Scholar
26 Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, like to left ventricular changes, narrate the cardiac low of septic daze in humans. Chest . 1990; 97: 126–131.CrossrefMedlineGoogle Scholar
27 Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate equally an early predictor of prognosis. Crit Intendance Med . 1987; 15: 923–929.CrossrefMedlineGoogle Scholar
28 Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM, Bennett ED. A prospective study of the use of a dobutamine stress examination to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med . 1999; 27: 2361–2366.CrossrefMedlineGoogle Scholar
29 Maeder One thousand, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest . 2006; 129: 1349–1366.CrossrefMedlineGoogle Scholar
thirty Fernandes CJ, Akamine Due north, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med . 1999; 25: 1165–1168.CrossrefMedlineGoogle Scholar
31 ver Elst KM, Spapen Hd, Nguyen DN, Garbar C, Huyghens LP, Gorus FK. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem . 2000; 46: 650–657.CrossrefMedlineGoogle Scholar
32 Ammann P, Fehr T, Minder EI, Gunter C, Bertel O. Meridian of troponin I in sepsis and septic shock. Intensive Care Med . 2001; 27: 965–969.CrossrefMedlineGoogle Scholar
33 Mehta NJ, Khan IA, Gupta V, Jani Grand, Gowda RM, Smith PR. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic daze. Int J Cardiol . 2004; 95: 13–17.CrossrefMedlineGoogle Scholar
34 Turner A, Tsamitros G, Bellomo R. Myocardial cell injury in septic stupor. Crit Care Med . 1999; 27: 1775–1780.CrossrefMedlineGoogle Scholar
35 Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani G, Gandini C. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med . 2000; 26: 31–37.CrossrefMedlineGoogle Scholar
36 Spies C, Haude V, Fitzner R, Schroder M, Overbeck M, Runkel North, Schaffartzik Westward. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest . 1998; 113: 1055–1063.CrossrefMedlineGoogle Scholar
37 Lim Westward, Qushmag I, Devereaux PJ, Heels-Ansdell D, Lauzier F, Ismaila As, Crowther MA, Cook DJ. Elevated cardiac troponin measurements in critically ill patients. Arch Intern Med . 2006; 166: 2446–2454.CrossrefMedlineGoogle Scholar
38 Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation . 1986; 73: 637–644.CrossrefMedlineGoogle Scholar
39 Herbertson MJ, Werner HA, Russell JA, Iversen Thou, Walley KR. Myocardial oxygen extraction ratio is decreased during endotoxemia in pigs. J Appl Physiol . 1995; 79: 479–486.CrossrefMedlineGoogle Scholar
forty Powell RJ, Machiedo GW, Blitz BF, Dikdan K. Oxygen free radicals: event on red cell deformability in sepsis. Crit Care Med . 1991; 19: 732–735.CrossrefMedlineGoogle Scholar
41 Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall'Ava-Santucci J, Brunet F, Villemant D, Carli A, Raichvarg D. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic daze. Circulation . 1987; 75: 533–541.CrossrefMedlineGoogle Scholar
42 Solomon MA, Correa R, Alexander Hour, Koev LA, Cobb JP, Kim DK, Roberts WC, Quezado ZM, Scholz TD, Cunnion RE, Hoffman WD, Bacher J, Yatsiv I, Danner RL, Banks SM, Ferrans VJ, Balaban RS, Natanson C. Myocardial free energy metabolism and morphology in a canine model of sepsis. Am J Physiol Heart Circ Physiol . 1994; 266: H757–H768.CrossrefMedlineGoogle Scholar
43 Van Lambalgen AA, van Kraats AA, Mulder MF, Teerlink T, van den Bos GC. High-energy phosphates in heart, liver, kidney, and skeletal muscle of endotoxemic rats. Am J Physiol Heart Circ Physiol . 1994; 266: H1581–H1587.CrossrefGoogle Scholar
44 Levy RJ, Piel DA, Acton PD, Zhou R, Ferrari VA, Karp JS, Deutschman CS. Evidence of myocardial hibernation in the septic middle. Crit Intendance Med . 2005; 33: 2752–2756.CrossrefMedlineGoogle Scholar
45 Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Intendance Med . 1996; 24: 1072–1078.CrossrefMedlineGoogle Scholar
46 Hoffmann R. Tissue Doppler echocardiography: already of clinical significance? Z Kardiol . 2002; 91: 677–684.CrossrefMedlineGoogle Scholar
47 Wiggers CJ. Myocardial depression in daze: a survey of cardiodynamic studies. Am Heart J . 1947; 33: 633–650.CrossrefMedlineGoogle Scholar
48 Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock: septic stupor patients with a reduced ejection fraction accept a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest . 1985; 76: 1539–1553.CrossrefMedlineGoogle Scholar
49 Hoffmann JN, Werdan Grand, Hartl WH, Jochum M, Faist East, Inthorn D. Hemofiltrate from patients with astringent sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock . 1999; 13: 174–180.Google Scholar
50 Mink SN, Jacobs H, Duke K, Bose D, Cheng ZQ, Calorie-free RB. N,N′,Northward″-triacetylglucosamine, an inhibitor of lysozyme, prevents myocardial low in Escherichia coli sepsis in dogs. Crit Care Med . 2004; 32: 184–193.CrossrefMedlineGoogle Scholar
51 Suffredini AF, Fromm RE, Parker MM, Brenner One thousand, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med . 1989; 321: 280–287.CrossrefMedlineGoogle Scholar
52 Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE. Endotoxemia in human septic stupor. Chest . 1991; 99: 169–175.CrossrefMedlineGoogle Scholar
53 Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic stupor. Chest . 1989; 95: 1072–1080.CrossrefMedlineGoogle Scholar
54 Sharma AC, Motew SJ, Farias S, Alden KJ, Bosmann HB, Law WR, Ferguson JL. Sepsis alters myocardial and plasma concentrations of endothelin and nitric oxide in rats. J Mol Cell Cardiol . 1997; 29: 1469–1477.CrossrefMedlineGoogle Scholar
55 Horton JW, Maass D, White J, Sanders B. Nitric oxide modulation of TNF-alpha-induced cardiac contractile dysfunction is concentration dependent. Am J Physiol Middle Circ Physiol . 2000; 278: H1955–H1965.CrossrefMedlineGoogle Scholar
56 Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont East. Administration of anti-TNF antibody improves left ventricular function in septic shock patients: results of a pilot study. Breast . 1992; 101: 810–815.CrossrefMedlineGoogle Scholar
57 Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E; the Soluble TNF Receptor Sepsis Written report Group. Treatment of septic daze with the tumor necrosis factor receptor:Fc fusion protein. North Engl J Med . 1996; 334: 1697–1702.CrossrefMedlineGoogle Scholar
58 Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A; Ro 45-2081 Study Group. p55 Tumor necrosis factor receptor fusion poly peptide in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA . 1997; 277: 1531–1538.CrossrefMedlineGoogle Scholar
59 Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman South, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S; NORASEPT II Written report Group. Double-bullheaded randomised controlled trial of monoclonal antibiotic to human neoplasm necrosis gene in treatment of septic shock. Lancet . 1998; 351: 929–933.CrossrefMedlineGoogle Scholar
60 Francis SE, Holden H, Holt CM, Duff GW. Interleukin-ane in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol . 1998; 30: 215–223.CrossrefMedlineGoogle Scholar
61 Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Cramp RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel Thou, Abraham E, Seneff M; Interleukin-1 Receptor Antagonist Sepsis Investigator Grouping. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Intendance Med . 1997; 25: 1115–1124.CrossrefMedlineGoogle Scholar
62 Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL; Phase 3 rhIL-1ra Sepsis Syndrome Written report Grouping. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA . 1994; 271: 1836–1843.CrossrefMedlineGoogle Scholar
63 Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during astringent sepsis in homo IL-6 as a mark of severity. Ann Surg . 1992; 215: 356–362.CrossrefMedlineGoogle Scholar
64 Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca²⁺-independent nitric oxide synthase in the myocardium. Br J Pharmacol . 1992; 105: 575–580.CrossrefMedlineGoogle Scholar
65 Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Scientific discipline . 1992; 257: 387–389.CrossrefMedlineGoogle Scholar
66 Liu SF, Newton R, Evans TW, Barnes PJ. Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 cistron expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci (Lond) . 1996; ninety: 301–306.CrossrefMedlineGoogle Scholar
67 Reines HD, Halushka PV, Melt JA, Wise WC, Rambo W. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet . 1982; two: 174–175.CrossrefMedlineGoogle Scholar
68 Fletcher JR, Ramwell Pw. Modification, by aspirin and indomethacin, of the haemodynamic and prostaglandin releasing effects of Eastward. coli endotoxin in the canis familiaris. Br J Pharmacol . 1977; 61: 175–181.CrossrefMedlineGoogle Scholar
69 Parratt JR, Sturgess RM. E. coli endotoxin shock in the cat; treatment with indomethacin. Br J Pharmacol . 1975; 53: 485–488.CrossrefMedlineGoogle Scholar
lxx Bernard GR, Wheeler AP, Russel JA, Schein R, Summertime WR, Steinberg KP, Fulkerson WJ, Wright PE, Christmann BW, Dupont WD, Higgins SB, Swindell BB; The Ibuprofen in Sepsis Study Group. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med . 1997; 336: 912–918.CrossrefMedlineGoogle Scholar
71 Memis D, Karamanlioglu B, Turan A, Koyuncu O, Pamukcu Z. Effects of lornoxicam on the physiology of astringent sepsis. Crit Care . 2004; 8: R474–R482.CrossrefMedlineGoogle Scholar
72 Tunctan B, Altug S, Uludag O, Demirkay B, Abacioglu N. Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis. Pharmacol Res . 2003; 48: 37–48.MedlineGoogle Scholar
73 Reddy RC, Chen GH, Tateda One thousand, Tsai WC, Phare SM, Mancuso P, Peters-Golden Chiliad, Standiford TJ. Selective inhibition of COX-two improves early survival in murine endotoxemia only not in bacterial peritonitis. Am J Physiol Lung Cell Mol Physiol . 2001; 281: L537–L543.CrossrefMedlineGoogle Scholar
74 Gupta A, Brahmbhatt S, Kapoor R, Loken L, Sharma AC. Chronic peritoneal sepsis: myocardial dysfunction, endothelin and signaling mechanisms. Front end Biosci . 2005; 10: 3183–3205.CrossrefMedlineGoogle Scholar
75 Shindo T, Kurihara H, Kurihara Y, Morita H, Yazaki Y. Upregulation of endothelin-1 and adrenomedullin cistron expression in the mouse endotoxin stupor model. J Cardiovasc Pharmacol . 1998; 31: S541–S544.CrossrefMedlineGoogle Scholar
76 Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ. Provisional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation . 2004; 109: 255–261.LinkGoogle Scholar
77 Konrad D, Oldner A, Rossi P, Wanecek M, Rudehill A, Weitzberg E. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin stupor. Crit Intendance Med . 2004; 32: 1192–1199.CrossrefMedlineGoogle Scholar
78 Schulz R, Rassaf T, Massion Lead, Kelm Thousand, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther . 2005; 108: 225–256.CrossrefMedlineGoogle Scholar
79 Rassaf T, Poll LW, Brouzos P, Lauer T, Totzeck M, Kleinbongard P, Gharini P, Andersen Thousand, Schulz R, Heusch Grand, Modder U, Kelm Chiliad. Positive effects of nitric oxide on left ventricular part in humans. Eur Heart J . 2006; 27: 1699–1705.CrossrefMedlineGoogle Scholar
lxxx Kelm One thousand, Schafer Southward, Dahmann R, Dolu B, Perings Southward, Decking Britain, Schrader J, Strauer Be. Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation. Cardiovasc Res . 1997; 36: 185–194.MedlineGoogle Scholar
81 Merx MW, Godecke A, Flogel U, Schrader J. Oxygen supply and nitric oxide scavenging by myoglobin contribute to do endurance and cardiac function. FASEB J . 2005; 19: 1015–1017.CrossrefMedlineGoogle Scholar
82 Heusch G, Post H, Michel MC, Kelm M, Schulz R. Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res . 2000; 87: 146–152.CrossrefMedlineGoogle Scholar
83 Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res . 2004; 61: 402–413.CrossrefMedlineGoogle Scholar
84 Preiser JC, Zhang H, Vray B, Hrabak A, Vincent JL. Time form of inducible nitric oxide synthase activeness following endotoxin administration in dogs. Nitric Oxide . 2001; v: 208–211.CrossrefMedlineGoogle Scholar
85 Khadour FH, Panas D, Ferdinandy P, Schulze C, Csont T, Lalu MM, Wildhirt SM, Schulz R. Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol . 2002; 283: H1108–H1115.CrossrefMedlineGoogle Scholar
86 Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in wellness and illness. Physiol Rev . 2007; 87: 315–424.CrossrefMedlineGoogle Scholar
87 Ullrich R, Scherrer-Crosbie Thousand, Bloch KD, Ichinose F, Nakajima H, Picard MH, Zapol WM, Quezado ZM. Congenital deficiency of nitric oxide synthase 2 protects confronting endotoxin-induced myocardial dysfunction in mice. Circulation . 2000; 102: 1440–1446.CrossrefMedlineGoogle Scholar
88 Hwang TL, Yeh CC. Hemodynamic and hepatic microcirculational changes in endotoxemic rats treated with different NOS inhibitors. Hepatogastroenterology . 2003; fifty: 188–191.MedlineGoogle Scholar
89 Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B, Nedashkovsky EV, Bjertanaes LJ. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled written report. Crit Care Med . 2001; 29: 1860–1867.CrossrefMedlineGoogle Scholar
90 Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res . 2000; 87: 241–247.CrossrefMedlineGoogle Scholar
91 Elfering SL, Sarkela TM, Giulivi C. Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem . 2002; 277: 38079–38086.CrossrefMedlineGoogle Scholar
92 Connelly L, Madhani 1000, Hobbs AJ. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived NO in vivo. J Biol Chem . 2005; 280: 10040–10046.CrossrefMedlineGoogle Scholar
93 Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax TW, Kumara I, Gharini P, Kabanova South, Ozuyaman B, Schnurch H-G, Gödecke A, Weber A-A, Robenek K, Robenek H, Bloch W, Rosen P, Kelm M. Cerise blood cells express a functional endothelial nitric oxide synthase. Blood . 2006; 107: 2943–2951.CrossrefMedlineGoogle Scholar
94 Raeburn CD, Calkins CM, Zimmerman MA, Song Y, Ao 50, Banerjee A, Harken AH, Meng X. ICAM-one and VCAM-i mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation. Am J Physiol Regul Integr Comp Physiol . 2002; 283: R477–R486.CrossrefMedlineGoogle Scholar
95 Neviere R, Guery B, Mordon Southward, Zerimech F, Charre Southward, Wattel F, Chopin C. Inhaled NO reduces leukocyte-endothelial cell interactions and myocardial dysfunction in endotoxemic rats. Am J Physiol Heart Circ Physiol . 2000; 278: H1783–H1790.CrossrefMedlineGoogle Scholar
96 Raeburn CD, Calkins CM, Zimmerman MA, Song Y, Ao L, Banerjee A, Meng X, Harken AH. Vascular cell adhesion molecule-1 expression is obligatory for endotoxin-induced myocardial neutrophil accumulation and contractile dysfunction. Surgery . 2001; 130: 319–325.CrossrefMedlineGoogle Scholar
97 Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med . 2004; 32: 858–873.CrossrefMedlineGoogle Scholar
98 Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard Then, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S. Practice parameters for hemodynamic back up of sepsis in adult patients: 2004 update. Crit Care Med . 2004; 32: 1928–1948.CrossrefMedlineGoogle Scholar
99 van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest . 1996; 97: 713–719.CrossrefMedlineGoogle Scholar
100 van der Poll T, Levi M, Dentener M, Jansen PM, Coyle SM, Braxton CC, Buurman WA, Hack CE, 10 Cate JW, Lowry SF. Epinephrine exerts anticoagulant effects during homo endotoxemia. J Exp Med . 1997; 185: 1143–1148.CrossrefMedlineGoogle Scholar
101 Lemaire 50, de Kruif M, Giebelen IA, Levi M, van der Poll T, Heesen Thousand. Dobutamine does non influence inflammatory pathways during man endotoxemia. Crit Care Med . 2006; 34: 1365–1371.CrossrefMedlineGoogle Scholar
102 Leone M, Boyadjiev I, Boulos Eastward, Antonini F, Visintini P, Albanese J, Martin C. A reappraisal of isoproterenol in goal-directed therapy of septic daze. Shock . 2006; 26: 353–357.CrossrefMedlineGoogle Scholar
103 Suzuki T, Morisaki H, Serita R, Yamamoto K, Kotake Y, Ishizaka A, Takeda J. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med . 2005; 33: 2294–2301.CrossrefMedlineGoogle Scholar
104 Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and rubber of recombinant human activated protein C for severe sepsis. Due north Engl J Med . 2001; 344: 699–709.CrossrefMedlineGoogle Scholar
105 Annane D. Corticosteroids for septic shock. Crit Care Med . 2001; 29: S117–S120.CrossrefMedlineGoogle Scholar
106 Tonelli Chiliad, Isles C, Chicken T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, W M, Packard C, Curhan GC. Event of pravastatin on rate of kidney function loss in people with or at take chances for coronary disease. Apportionment . 2005; 112: 171–178.LinkGoogle Scholar
107 Fukuta H, Sane DC, Brucks South, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic center failure: a preliminary report. Apportionment . 2005; 112: 357–363.LinkGoogle Scholar
108 Zhang 50, Zhang ZG, Ding GL, Jiang Q, Liu Ten, Meng H, Hozeska A, Zhang C, Li L, Morris D, Zhang RL, Lu 1000, Chopp M. Multitargeted furnishings of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Apportionment . 2005; 112: 3486–3494.LinkGoogle Scholar
109 Kwak B, Mulhaupt F, Myit S, Mach F. Statins equally a newly recognized blazon of immunomodulator. Nat Med . 2000; 6: 1399–1402.CrossrefMedlineGoogle Scholar
110 Kurakata Due south, Kada M, Shimada Y, Komai T, Nomoto Thou. Effects of dissimilar inhibitors of 3-hydroxy-three-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology . 1996; 34: 51–61.CrossrefMedlineGoogle Scholar
111 Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti North, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest . 2000; eighty: 1095–1100.CrossrefMedlineGoogle Scholar
112 Weber C, Erl Westward, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol . 1997; 30: 1212–1217.CrossrefMedlineGoogle Scholar
113 Yoshida Grand, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow weather in vitro: involvement of Rho GTPase-dependent machinery. Arterioscler Thromb Vasc Biol . 2001; 21: 1165–1171.CrossrefMedlineGoogle Scholar
114 Weitz-Schmidt Thou, Welzenbach K, Brinkmann Five, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 past binding to a novel regulatory integrin site. Nat Med . 2001; 7: 687–692.CrossrefMedlineGoogle Scholar
115 Colli Due south, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human being macrophages: a novel mechanism of protection confronting atherothrombosis. Arterioscler Thromb Vasc Biol . 1997; 17: 265–272.CrossrefMedlineGoogle Scholar
116 Erkkila L, Jauhiainen Thousand, Laitinen Yard, Haasio K, Tiirola T, Saikku P, Leinonen 1000. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother . 2005; 49: 3959–3962.CrossrefMedlineGoogle Scholar
117 del Real G, Jimenez-Baranda Due south, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret Grand, Pena JM, Rodriguez-Zapata M, Alvarez-Mon K, Martinez A, Manes S. Statins inhibit HIV-1 infection by downwards-regulating Rho activeness. J Exp Med . 2004; 200: 541–547.CrossrefMedlineGoogle Scholar
118 Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on bloodshed in patients with bacteremia. Clin Infect Dis . 2001; 33: 1352–1357.CrossrefMedlineGoogle Scholar
119 Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn One thousand, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW. Simvastatin blunts endotoxin-induced tissue factor in vivo. Apportionment . 2005; 111: 1841–1846.LinkGoogle Scholar
120 Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of astringent sepsis. Circulation . 2004; 110: 880–885.LinkGoogle Scholar
121 Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet . 2006; 367: 413–418.CrossrefMedlineGoogle Scholar
122 Merx MW, Weber C. Statins: a preventive strike against sepsis in patients with cardiovascular disease? Lancet . 2006; 367: 372–373.CrossrefMedlineGoogle Scholar
123 Panacek EA, Marshall JC, Alberson TE, Johnson DH, Johnson S, MacArthur RD, Miller Yard, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum Fifty, Lemeshow S, Hicklin Grand, Doig C. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Intendance Med . 2004; 32: 2173–2182.CrossrefMedlineGoogle Scholar
124 Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E; EZZI Study Group. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with astringent sepsis. Crit Care Med . 2005; 33: 1741–1748.CrossrefMedlineGoogle Scholar
125 Grandel U, Hopf K, Buerke Thousand, Hattar Thousand, Heep M, Fink Fifty, Bohle RM, Morath S, Hartung T, Pullamsetti S, Schermuly RT, Seeger Due west, Grimminger F, Sibelius U. Mechanisms of cardiac depression caused past lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation . 2005; 112: 691–698.LinkGoogle Scholar